{
    "nctId": "NCT03535701",
    "briefTitle": "Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer",
    "officialTitle": "Ketogenic Diet and Chemotherapy to Affect Recurrence of Breast Cancer (The KETO-CARE Study)",
    "overallStatus": "COMPLETED",
    "conditions": "Stage IV Breast Cancer AJCC v6 and v7",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Adherence and compliance to the ketogenic diet",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Body mass index (BMI) \\>= 22 kg/m\\^2\n* Confirmed diagnosis of metastatic or stage IV BC\n* Fludeoxyglucose F-18 (FDG)-positron emission tomography (PET) avid tumors\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (0=participant has either normal activity, 1= participant has some symptoms but is nearly full ambulatory)\n* Life expectancy \\> 6 months\n* Able and willing to follow prescribed diet intervention\n\nExclusion Criteria:\n\n* Prior chemotherapy for metastatic breast cancer (MBC) (prior adjuvant chemotherapy permitted as long as \\> 12 months \\[mo\\])\n* BMI \\< 25 kg/m\\^2\n* Weight change \\> 5% within 3 months of enrollment\n* Type 1 diabetes\n* History of diabetes with retinopathy requiring treatment\n* Current use of insulin or sulfonylureads for glycemic control, or history of ketoacidosis\n* Intestinal obstruction\n* Bilirubin \\> 2\n* Albumin \\< 3.5\n* Glomerular filtration rate (GFR) \\< 55 mL/min\n* Creatinine \\> 2.0\n* Urinary albumin \\> 1 g/day\n* Congestive heart failure\n* Pregnant or nursing women\n* Unable to provide informed consent\n* Uncontrolled concurrent medical conditions that would limit compliance with study requirements",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}